InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development | $10.3M-44.9% | $18.7M-14.0% | $21.7M |
| General and administrative | $12.2M+88.2% | $6.5M+98.6% | $3.3M |
| Total operating expenses | $22.5M-10.6% | $25.2M+0.7% | $25.0M |
| Loss from operations | -$22.5M+10.6% | -$25.2M-0.7% | -$25.0M |
| Change in estimated fair value of warrant liability | $0+100.0% | -$79K+1.2% | -$80K |
| Gain on settlement of warrants | $0-100.0% | $343K | $0 |
| Loss on issuance of related party convertible notes payable at fair value | $0+100.0% | -$400K | $0 |
| Change in estimated fair value of related party convertible notes payable | $0+100.0% | -$2.2M | $0 |
| Interest expense | -$20K-8.2% | -$19K+57.1% | -$44K |
| Interest income | $288K+29.4% | $222K-37.0% | $353K |
| Total other income (expense), net | $267K+112.6% | -$2.1M-1026.9% | $229K |
| Net loss | -$22.2M+18.5% | -$27.3M-10.3% | -$24.7M |
| Weighted-average shares of common stock outstanding, basic | $21.0M+151.1% | $8.4M+483.5% | $1.4M |
| Weighted-average shares of common stock outstanding, diluted | $21.0M+151.1% | $8.4M+483.5% | $1.4M |
| Net loss per share attributable to common stockholders, basic | -$1.06+67.5% | -$3.26+81.1% | -$17.24 |
| Net loss per share attributable to common stockholders, diluted | -$1.06+67.5% | -$3.26+81.1% | -$17.24 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers